RadNet Förvaltning
Förvaltning kriterier kontrolleras 2/4
RadNet VD är Howard Berger, utsedd i Jan 1987, har en mandatperiod på 39.33 år. totala årliga ersättningen är $ 12.09M, bestående av 24.8% lön 75.2% bonusar, inklusive företagsaktier och optioner. äger direkt 0.58% av företagets aktier, värda $ 25.57M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 9 år respektive 13.8 år.
Viktig information
Howard Berger
Verkställande direktör
US$12.1m
Total ersättning
| VD-lön i procent | 24.82% |
| Anställning som VD | 39.3yrs |
| Ägande av VD | 0.6% |
| Ledningens genomsnittliga anställningstid | 9yrs |
| Styrelsens genomsnittliga mandatperiod | 13.8yrs |
Senaste uppdateringar av ledningen
Recent updates
RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility
Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility
RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside
Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside
Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside
Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside
Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside
Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance
Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance
Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance
Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts
Nov 14
RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings
RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential
Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Sep 12AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.RadNet: Bloated Capital Base Not Pulling Its Economic Weight (Rating Downgrade)
Aug 18Some Confidence Is Lacking In RadNet, Inc.'s (NASDAQ:RDNT) P/S
Jul 31RadNet (NASDAQ:RDNT) May Have Issues Allocating Its Capital
Jul 15We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt
Jun 10RadNet, Inc. (NASDAQ:RDNT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 15Is There An Opportunity With RadNet, Inc.'s (NASDAQ:RDNT) 37% Undervaluation?
May 07Is RadNet, Inc. (NASDAQ:RDNT) Potentially Undervalued?
Apr 24Returns On Capital Signal Tricky Times Ahead For RadNet (NASDAQ:RDNT)
Apr 11RadNet: On The Sidelines For Now
Mar 11There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Price
Feb 16A Look At The Fair Value Of RadNet, Inc. (NASDAQ:RDNT)
Jan 31Does RadNet (NASDAQ:RDNT) Have A Healthy Balance Sheet?
Jan 16Is It Time To Consider Buying RadNet, Inc. (NASDAQ:RDNT)?
Jan 01There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Massive 26% Price Jump
Nov 12Here's What To Make Of RadNet's (NASDAQ:RDNT) Decelerating Rates Of Return
Oct 15RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects
Oct 02Unpleasant Surprises Could Be In Store For RadNet, Inc.'s (NASDAQ:RDNT) Shares
Sep 22
Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector
Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.RadNet: Growth In Operating Earnings Off Very Little Incremental Capital
Aug 24RadNet (NASDAQ:RDNT) Seems To Use Debt Quite Sensibly
Jul 22Returns On Capital At RadNet (NASDAQ:RDNT) Have Stalled
Jun 05RadNet: Qualified Growth Route, Still Undervalued
Jun 05Is There Now An Opportunity In RadNet, Inc. (NASDAQ:RDNT)?
May 10Are RadNet, Inc. (NASDAQ:RDNT) Investors Paying Above The Intrinsic Value?
Apr 08RadNet, Inc.'s (NASDAQ:RDNT) 26% Price Boost Is Out Of Tune With Revenues
Mar 06Why RadNet, Inc. (NASDAQ:RDNT) Could Be Worth Watching
Feb 08RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation
Jan 28Getting In Cheap On RadNet, Inc. (NASDAQ:RDNT) Might Be Difficult
Dec 28We Think RadNet (NASDAQ:RDNT) Can Stay On Top Of Its Debt
Dec 04RadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital Effectively
Aug 27RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Aug 09We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt
Mar 30RadNet (NASDAQ:RDNT) Will Want To Turn Around Its Return Trends
Feb 19Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$19m |
| Sep 30 2025 | n/a | n/a | -US$13m |
| Jun 30 2025 | n/a | n/a | -US$15m |
| Mar 31 2025 | n/a | n/a | -US$32m |
| Dec 31 2024 | US$9m | US$3m | US$3m |
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | n/a | n/a | US$10m |
| Mar 31 2024 | n/a | n/a | US$21m |
| Dec 31 2023 | US$7m | US$2m | US$3m |
| Sep 30 2023 | n/a | n/a | US$4m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$6m | US$2m | US$11m |
| Sep 30 2022 | n/a | n/a | US$8m |
| Jun 30 2022 | n/a | n/a | US$23m |
| Mar 31 2022 | n/a | n/a | US$18m |
| Dec 31 2021 | US$5m | US$1m | US$25m |
| Sep 30 2021 | n/a | n/a | US$35m |
| Jun 30 2021 | n/a | n/a | US$24m |
| Mar 31 2021 | n/a | n/a | US$11m |
| Dec 31 2020 | US$3m | US$783k | -US$15m |
| Sep 30 2020 | n/a | n/a | -US$10m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | US$2m |
| Dec 31 2019 | US$3m | US$1m | US$15m |
Ersättning vs marknad: Howard s total kompensation ($USD 12.09M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 7.19M ).
Ersättning vs inkomst: Ersättningen för Howard har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Howard Berger (79 yo)
39.3yrs
Anställning
US$12,087,934
Kompensation
Dr. Howard G. Berger, M.D., serves as the President and Chief Financial Officer of Image Medical Corporation. Dr. Berger has been the Chief Executive Officer and President at RadNet, Inc. and its predecess...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Chairman | 39.3yrs | US$12.09m | 0.58% $ 25.6m | |
| Executive VP & CFO | 21.8yrs | US$2.83m | 0.16% $ 6.9m | |
| Executive VP & COO | less than a year | US$3.06m | 0.26% $ 11.3m | |
| President & CEO of Western Operations | no data | US$3.24m | 0.34% $ 15.1m | |
| President & CEO of Eastern Operations | 9yrs | US$3.25m | 0.69% $ 30.7m | |
| Executive VP | 2.8yrs | US$2.56m | 1.54% $ 68.0m | |
| Chief Information Officer | less than a year | inga uppgifter | inga uppgifter | |
| Senior Vice President of Compliance & Regulatory Affairs | 9.2yrs | inga uppgifter | inga uppgifter | |
| Executive VP | 6.2yrs | inga uppgifter | 0.12% $ 5.1m | |
| Executive Vice President of Mergers & Acquisitions | 19.3yrs | inga uppgifter | 0.060% $ 2.6m | |
| Senior VP & Director of Materials & Asset Management | 23.3yrs | inga uppgifter | inga uppgifter | |
| SVP of Healthcare Network Strategy & Business Development - Eastern Operations | 8.8yrs | inga uppgifter | inga uppgifter |
9.0yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder
Erfaren ledning: RDNT s ledningsgrupp är erfaren och erfaren ( 9 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Chairman | 34.3yrs | US$12.09m | 0.58% $ 25.6m | |
| Executive VP | 2.8yrs | US$2.56m | 1.54% $ 68.0m | |
| Lead Independent Director | 22.3yrs | US$308.52k | 0.27% $ 12.1m | |
| Independent Director | 4.9yrs | US$251.02k | 0.0068% $ 299.2k | |
| Independent Director | 21.3yrs | US$273.52k | 0.21% $ 9.3m | |
| Independent Director | 6.3yrs | US$268.52k | 0.035% $ 1.5m |
13.8yrs
Genomsnittlig anställningstid
73yo
Genomsnittlig ålder
Erfaren styrelse: RDNT s styrelse är rutinerade och erfaren ( 13.8 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/01 00:28 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
RadNet, Inc. bevakas av 12 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Sarah James | Barclays |
| Andrew Mok | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |